JP2018513104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513104A5 JP2018513104A5 JP2017534274A JP2017534274A JP2018513104A5 JP 2018513104 A5 JP2018513104 A5 JP 2018513104A5 JP 2017534274 A JP2017534274 A JP 2017534274A JP 2017534274 A JP2017534274 A JP 2017534274A JP 2018513104 A5 JP2018513104 A5 JP 2018513104A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nanoparticles
- cancer
- malignant tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000002105 nanoparticle Substances 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 108091030071 RNAI Proteins 0.000 claims 4
- 230000009368 gene silencing by RNA Effects 0.000 claims 4
- 101150018337 Serpinh1 gene Proteins 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014266198 | 2014-12-26 | ||
| JP2014266198 | 2014-12-26 | ||
| US201562184195P | 2015-06-24 | 2015-06-24 | |
| US62/184,195 | 2015-06-24 | ||
| US201562266670P | 2015-12-13 | 2015-12-13 | |
| US62/266,670 | 2015-12-13 | ||
| PCT/US2015/067558 WO2016106403A2 (en) | 2014-12-26 | 2015-12-28 | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513104A JP2018513104A (ja) | 2018-05-24 |
| JP2018513104A5 true JP2018513104A5 (cg-RX-API-DMAC7.html) | 2019-02-14 |
Family
ID=56151549
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534275A Pending JP2018512373A (ja) | 2014-12-26 | 2015-12-28 | Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 |
| JP2017534294A Active JP6730285B2 (ja) | 2014-12-26 | 2015-12-28 | Ｒｎａ干渉組成物及び悪性腫瘍のための方法 |
| JP2017534279A Active JP6865169B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ干渉剤 |
| JP2017534297A Active JP6457645B2 (ja) | 2014-12-26 | 2015-12-28 | ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2017534274A Pending JP2018513104A (ja) | 2014-12-26 | 2015-12-28 | Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法 |
| JP2017534286A Active JP6793649B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ剤 |
| JP2017534287A Pending JP2018513669A (ja) | 2014-12-26 | 2015-12-28 | Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤 |
| JP2021183788A Active JP7307137B2 (ja) | 2014-12-26 | 2021-11-11 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2023106970A Active JP7655971B2 (ja) | 2014-12-26 | 2023-06-29 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2025046972A Pending JP2025102833A (ja) | 2014-12-26 | 2025-03-21 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534275A Pending JP2018512373A (ja) | 2014-12-26 | 2015-12-28 | Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 |
| JP2017534294A Active JP6730285B2 (ja) | 2014-12-26 | 2015-12-28 | Ｒｎａ干渉組成物及び悪性腫瘍のための方法 |
| JP2017534279A Active JP6865169B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ干渉剤 |
| JP2017534297A Active JP6457645B2 (ja) | 2014-12-26 | 2015-12-28 | ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534286A Active JP6793649B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ剤 |
| JP2017534287A Pending JP2018513669A (ja) | 2014-12-26 | 2015-12-28 | Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤 |
| JP2021183788A Active JP7307137B2 (ja) | 2014-12-26 | 2021-11-11 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2023106970A Active JP7655971B2 (ja) | 2014-12-26 | 2023-06-29 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2025046972A Pending JP2025102833A (ja) | 2014-12-26 | 2025-03-21 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (14) | US10264976B2 (cg-RX-API-DMAC7.html) |
| EP (9) | EP3798308A1 (cg-RX-API-DMAC7.html) |
| JP (10) | JP2018512373A (cg-RX-API-DMAC7.html) |
| KR (4) | KR102527430B1 (cg-RX-API-DMAC7.html) |
| CN (7) | CN107108686B (cg-RX-API-DMAC7.html) |
| AU (4) | AU2015369592B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112017013599A2 (cg-RX-API-DMAC7.html) |
| CA (4) | CA2971881C (cg-RX-API-DMAC7.html) |
| RU (4) | RU2719185C2 (cg-RX-API-DMAC7.html) |
| WO (7) | WO2016106406A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11045488B2 (en) * | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| US10792299B2 (en) * | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| ES2789049T3 (es) * | 2014-12-26 | 2020-10-23 | Nitto Denko Corp | Agentes de interferencia de ARN para modulación génica de GST-pi |
| AU2016281685B2 (en) * | 2015-06-24 | 2021-08-12 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
| US10358647B2 (en) | 2015-12-13 | 2019-07-23 | Nitto Denko Corporation | siRNA structures for high activity and reduced off target |
| TWI780046B (zh) | 2016-05-10 | 2022-10-11 | 國立大學法人東京醫科齒科大學 | 炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法 |
| JP2019508379A (ja) * | 2017-02-16 | 2019-03-28 | 日東電工株式会社 | 悪性腫瘍に対する治療方法及び治療用組成物 |
| WO2019090359A1 (en) * | 2017-11-06 | 2019-05-09 | Nitto Denko Corporation | Fusogenic compounds for delivery of biologically active molecules |
| SG11202004097RA (en) * | 2017-11-09 | 2020-06-29 | Univ Nat Corp Tokyo Medical & Dental | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method |
| CN109777798A (zh) * | 2017-11-13 | 2019-05-21 | 深圳华大生命科学研究院 | 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用 |
| JP6952594B2 (ja) * | 2017-12-15 | 2021-10-20 | 洋司郎 新津 | 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 |
| CN108486011B (zh) * | 2018-03-27 | 2020-05-05 | 山东大学 | 一种三联苯化合物、制备方法及其应用 |
| JP7432929B2 (ja) * | 2018-05-31 | 2024-02-19 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途 |
| WO2020009189A1 (ja) * | 2018-07-05 | 2020-01-09 | 洋司郎 新津 | Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤 |
| US20210310005A1 (en) * | 2018-08-22 | 2021-10-07 | Nitto Denko Corporation | Agent using hsp47 inhibitor to suppress metastasis |
| JP7453145B2 (ja) * | 2018-08-22 | 2024-03-19 | 日東電工株式会社 | Ｈｓｐ４７の阻害物質を用いた、化学療法剤感受性の増強 |
| EP4365289A3 (en) * | 2018-11-16 | 2024-07-10 | Nitto Denko Corporation | Rna interference delivery formulation and methods for malignant tumors |
| EP3906930A4 (en) * | 2018-12-05 | 2022-08-24 | Nitto Denko Corporation | RNAI MOLECULE FOR TREATMENT OF CANCER |
| US20220202846A1 (en) | 2019-01-10 | 2022-06-30 | Osaka University | Immunostimulating composition |
| CN113677373A (zh) * | 2019-03-28 | 2021-11-19 | 日东电工株式会社 | RNAi分子 |
| JP2019116507A (ja) * | 2019-04-25 | 2019-07-18 | 有限会社オービット | Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法 |
| CA3143404C (en) * | 2019-07-02 | 2024-03-05 | Argonaute RNA Limited | Apolipoprotein b antagonist |
| EP4005602A4 (en) * | 2019-07-30 | 2024-06-12 | Shionogi & Co., Ltd | NUCLEIC ACID AGENT TARGETED AGAINST MURF1 |
| EP4090744A4 (en) * | 2020-01-17 | 2024-04-10 | Anastasia Khvorova | UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS |
| CN112280800B (zh) * | 2020-10-19 | 2022-06-07 | 上海市东方医院（同济大学附属东方医院） | 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用 |
| AU2021411103B2 (en) * | 2020-12-28 | 2025-04-24 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
| EP4267742A2 (en) | 2020-12-28 | 2023-11-01 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
| KR102732909B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732911B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732912B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732913B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732910B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| US20250290076A1 (en) * | 2022-04-27 | 2025-09-18 | Kyoto University | Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration |
| TW202529777A (zh) * | 2023-09-28 | 2025-08-01 | 日商日東電工股份有限公司 | 組合療法 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3012244B2 (ja) | 1987-09-21 | 2000-02-21 | ジェン―プローブ インコーポレイテッド | ヌクレオチドプローブ用非ヌクレオチド連結試薬 |
| US5204241A (en) | 1990-10-22 | 1993-04-20 | Oxi-Gene Inc. | Glutathione-S-transferase mu as a measure of drug resistance |
| US5786336A (en) | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
| US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
| WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| JPH09504297A (ja) | 1993-10-27 | 1997-04-28 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ２′−アミドおよび２′−ペプチド修飾オリゴヌクレオチド |
| JPH11507056A (ja) | 1995-06-07 | 1999-06-22 | テラピン テクノロジーズ、インク． | グルタチオンアナログの代謝的効果 |
| US5968737A (en) | 1996-11-12 | 1999-10-19 | The University Of Mississippi | Method of identifying inhibitors of glutathione S-transferase (GST) gene expression |
| JPH10330249A (ja) * | 1997-05-30 | 1998-12-15 | Kureha Chem Ind Co Ltd | レチノール化合物含有ｈｓｐ４７合成抑制剤 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2328731A1 (en) | 1998-04-16 | 1999-10-28 | Atsushi Imaizumi | Glutathione derivatives and dosage forms thereof |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20070083945A1 (en) | 2000-03-10 | 2007-04-12 | Byrum Joseph R | Nucleic acid molecules and other molecules associated with plants |
| US20030144236A1 (en) | 2000-03-29 | 2003-07-31 | Weiss Robert H | Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1) |
| US20030165843A1 (en) | 2000-07-28 | 2003-09-04 | Avi Shoshan | Oligonucleotide library for detecting RNA transcripts and splice variants that populate a transcriptome |
| EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
| AU2004266311B2 (en) * | 2001-05-18 | 2009-07-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
| US20040219600A1 (en) | 2002-12-13 | 2004-11-04 | Williams Robert Wood | Method for determining sensitivity to environmental toxins and susceptibility to parkinson's disease |
| AU2003224132A1 (en) | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| US20050142596A1 (en) | 2003-11-14 | 2005-06-30 | Krolewski Andrzej S. | Methods of diagnosing renal and cardiovascular disease |
| EP2514758B2 (en) | 2004-03-15 | 2021-06-23 | City of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2005111211A2 (en) | 2004-05-14 | 2005-11-24 | Rosetta Genomics Ltd. | Micronas and uses thereof |
| NZ553910A (en) | 2004-08-26 | 2009-05-31 | Engeneic Molecular Delivery Pty | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| CA2595517C (en) | 2004-12-22 | 2013-09-24 | Sapporo Medical University | Drug carrier and drug carrier kit for inhibiting fibrosis |
| US9393315B2 (en) * | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| US8895717B2 (en) | 2005-04-15 | 2014-11-25 | The Board Of Regents Of The University Of Texas System | Delivery of siRNA by neutral lipid compositions |
| US20070134687A1 (en) * | 2005-09-12 | 2007-06-14 | Aurelium Biopharma Inc. | Focused microarray and methods of diagnosing cancer |
| ES2324128A1 (es) * | 2005-09-29 | 2009-07-30 | Proyecto De Biomedicina Cima, S.L. | Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares. |
| US20090220956A1 (en) * | 2005-10-25 | 2009-09-03 | Dimitry Serge Antoine Nuyten | Prediction of Local Recurrence of Breast Cancer |
| US20070197460A1 (en) | 2005-11-01 | 2007-08-23 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
| RU2448974C2 (ru) * | 2005-11-01 | 2012-04-27 | Элнилэм Фармасьютикалз, Инк. | РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА |
| EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
| DE602006005084D1 (de) | 2005-11-17 | 2009-03-19 | Childrens Medical Center | Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen |
| US7729737B2 (en) | 2005-11-22 | 2010-06-01 | Isense Corporation | Method and apparatus for background current arrangements for a biosensor |
| ES2419106T3 (es) | 2005-12-01 | 2013-08-19 | Pronai Therapeutics, Inc. | Formulación de liposomas anfóteros |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| US9572886B2 (en) * | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| WO2007130604A2 (en) * | 2006-05-04 | 2007-11-15 | Baylor Research Institute | Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna |
| EP2835429B1 (en) | 2006-05-11 | 2017-12-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
| WO2008109432A2 (en) | 2007-03-02 | 2008-09-12 | The Board Of Regents Of The University Of Texas System | Therapeutic targeting of interleukins using sirna in neutral liposomes |
| TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
| WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| EP2316943B1 (en) * | 2007-07-05 | 2013-06-19 | Novartis AG | DSRNA for treating viral infection |
| EP3121281B1 (en) | 2007-08-27 | 2021-03-31 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| WO2009033284A1 (en) | 2007-09-14 | 2009-03-19 | Mcmaster University | Inhibitors of collagen biosynthesis as anti-tumor agents |
| CA2715796C (en) * | 2008-03-06 | 2015-04-28 | Rottapharm S.P.A. | 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| EP2321414B1 (en) | 2008-07-25 | 2018-01-10 | Alnylam Pharmaceuticals, Inc. | Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand |
| US20100028416A1 (en) * | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
| EP2496700B1 (en) * | 2009-11-04 | 2017-03-01 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| AU2010328104B2 (en) | 2009-12-09 | 2014-10-30 | Nitto Denko Corporation | Modulation of hsp47 expression |
| MX341178B (es) | 2010-02-24 | 2016-08-10 | Bodysync Inc * | Metodos para determinar interacciones de gen-nutriente. |
| WO2011112954A1 (en) | 2010-03-12 | 2011-09-15 | The Wistar Institute | Inhibition of p21 and use thereof for inducing tissue regeneration |
| US8372819B2 (en) * | 2010-04-11 | 2013-02-12 | Salk Institute For Biological Studies | Methods and compositions for targeting skip |
| US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| US20130052169A1 (en) | 2010-05-06 | 2013-02-28 | Stem Cell Medicine Ltd. | Stem cell bank for personalized medicine |
| JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| AU2011307259A1 (en) | 2010-09-30 | 2013-05-02 | Nitto Denko Corporation | Modulation of TIMP1 and TIMP2 expression |
| US9339513B2 (en) | 2010-11-09 | 2016-05-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
| US9011903B2 (en) * | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| ES2570184T3 (es) | 2011-06-08 | 2016-05-17 | Nitto Denko Corp | Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip |
| ES2708932T3 (es) * | 2011-06-21 | 2019-04-12 | Nitto Denko Corp | Agente inductor de apoptosis |
| CN102896619B (zh) * | 2011-07-26 | 2015-04-22 | 苏州宝时得电动工具有限公司 | 动力工具及其操作方法 |
| CA2846074A1 (en) * | 2011-08-31 | 2013-05-10 | Alexzander A. Asea | Compositions and methods for treatment of metastatic cancer |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| WO2013075140A1 (en) * | 2011-11-17 | 2013-05-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Auto -recognizing therapeutic rna/dna chimeric nanoparticles (np) |
| EP2849762A4 (en) * | 2012-05-16 | 2016-02-24 | Aadigen Llc | MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY DISORDERS |
| US20140134158A1 (en) | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| CA2876148C (en) * | 2012-06-08 | 2021-01-12 | Nitto Denko Corporation | Lipids for therapeutic agent delivery formulations |
| WO2013192364A1 (en) | 2012-06-22 | 2013-12-27 | The University Of Vermont And State Agricultural College | Treatments of oxidative stress conditions |
| US9066938B2 (en) * | 2012-07-02 | 2015-06-30 | Fibrostein, S.L. | GPBP-1 inhibition and its therapeutic use |
| AU2013296321B2 (en) * | 2012-08-03 | 2019-05-16 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| KR102255108B1 (ko) | 2013-03-08 | 2021-05-24 | 노파르티스 아게 | 활성제의 전달을 위한 지질 및 지질 조성물 |
| CN103695421B (zh) * | 2013-12-09 | 2016-06-15 | 浙江大学 | 一种特异抑制p21基因表达的siRNA及其应用 |
| US10792299B2 (en) * | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| WO2016104588A1 (ja) * | 2014-12-26 | 2016-06-30 | 日東電工株式会社 | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 |
| US20160187319A1 (en) * | 2014-12-26 | 2016-06-30 | Nitto Denko Corporation | Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth |
| US10358647B2 (en) * | 2015-12-13 | 2019-07-23 | Nitto Denko Corporation | siRNA structures for high activity and reduced off target |
| JP6899201B2 (ja) | 2016-06-23 | 2021-07-07 | 日東電工株式会社 | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 |
-
2015
- 2015-11-06 US US14/934,665 patent/US10264976B2/en not_active Expired - Fee Related
- 2015-12-28 JP JP2017534275A patent/JP2018512373A/ja active Pending
- 2015-12-28 WO PCT/US2015/067561 patent/WO2016106406A2/en not_active Ceased
- 2015-12-28 WO PCT/US2015/067557 patent/WO2016106402A1/en not_active Ceased
- 2015-12-28 WO PCT/US2015/067559 patent/WO2016106404A2/en not_active Ceased
- 2015-12-28 RU RU2017126613A patent/RU2719185C2/ru active
- 2015-12-28 RU RU2017126610A patent/RU2756253C2/ru active
- 2015-12-28 AU AU2015369592A patent/AU2015369592B2/en active Active
- 2015-12-28 AU AU2015369595A patent/AU2015369595A1/en not_active Abandoned
- 2015-12-28 JP JP2017534294A patent/JP6730285B2/ja active Active
- 2015-12-28 AU AU2015369596A patent/AU2015369596A1/en not_active Abandoned
- 2015-12-28 KR KR1020177020898A patent/KR102527430B1/ko active Active
- 2015-12-28 CN CN201580071233.3A patent/CN107108686B/zh active Active
- 2015-12-28 EP EP20207751.7A patent/EP3798308A1/en active Pending
- 2015-12-28 JP JP2017534279A patent/JP6865169B2/ja active Active
- 2015-12-28 CN CN201580071210.2A patent/CN108064153A/zh active Pending
- 2015-12-28 JP JP2017534297A patent/JP6457645B2/ja active Active
- 2015-12-28 US US14/979,566 patent/US9771582B2/en not_active Ceased
- 2015-12-28 EP EP15874366.6A patent/EP3240796B1/en active Active
- 2015-12-28 CN CN201580071234.8A patent/CN108024961A/zh active Pending
- 2015-12-28 CA CA2971881A patent/CA2971881C/en active Active
- 2015-12-28 EP EP15874365.8A patent/EP3236969A4/en not_active Withdrawn
- 2015-12-28 US US14/979,568 patent/US10405749B2/en active Active
- 2015-12-28 JP JP2017534274A patent/JP2018513104A/ja active Pending
- 2015-12-28 KR KR1020177020900A patent/KR20170096199A/ko not_active Withdrawn
- 2015-12-28 KR KR1020177020894A patent/KR20170098929A/ko not_active Withdrawn
- 2015-12-28 EP EP15874362.5A patent/EP3236975A4/en not_active Ceased
- 2015-12-28 CN CN201580071191.3A patent/CN107106591B/zh active Active
- 2015-12-28 US US14/979,567 patent/US10047110B2/en active Active
- 2015-12-28 CN CN201580071209.XA patent/CN107106592B/zh active Active
- 2015-12-28 CN CN201580071081.7A patent/CN108064155B/zh active Active
- 2015-12-28 RU RU2017126598A patent/RU2017126598A/ru not_active Application Discontinuation
- 2015-12-28 WO PCT/US2015/067556 patent/WO2016106401A2/en not_active Ceased
- 2015-12-28 RU RU2017126601A patent/RU2017126601A/ru unknown
- 2015-12-28 EP EP20156350.9A patent/EP3683309A1/en active Pending
- 2015-12-28 US US14/979,571 patent/US9695206B2/en active Active
- 2015-12-28 CN CN201580071232.9A patent/CN107106564A/zh active Pending
- 2015-12-28 WO PCT/US2015/067560 patent/WO2016106405A1/en not_active Ceased
- 2015-12-28 EP EP15874367.4A patent/EP3236973A4/en not_active Withdrawn
- 2015-12-28 EP EP15874363.3A patent/EP3236976B1/en active Active
- 2015-12-28 EP EP15874364.1A patent/EP3236945B1/en active Active
- 2015-12-28 WO PCT/US2015/067553 patent/WO2016106400A2/en not_active Ceased
- 2015-12-28 US US14/979,577 patent/US20160215286A1/en not_active Abandoned
- 2015-12-28 CA CA2972270A patent/CA2972270A1/en not_active Abandoned
- 2015-12-28 BR BR112017013599-0A patent/BR112017013599A2/pt not_active Application Discontinuation
- 2015-12-28 CA CA2972268A patent/CA2972268A1/en not_active Abandoned
- 2015-12-28 EP EP15874361.7A patent/EP3236974B9/en active Active
- 2015-12-28 WO PCT/US2015/067558 patent/WO2016106403A2/en not_active Ceased
- 2015-12-28 BR BR112017013597-3A patent/BR112017013597B1/pt active IP Right Grant
- 2015-12-28 AU AU2015369598A patent/AU2015369598A1/en not_active Abandoned
- 2015-12-28 KR KR1020177020901A patent/KR20170093988A/ko not_active Withdrawn
- 2015-12-28 JP JP2017534286A patent/JP6793649B2/ja active Active
- 2015-12-28 US US14/979,573 patent/US9580710B2/en not_active Ceased
- 2015-12-28 JP JP2017534287A patent/JP2018513669A/ja active Pending
- 2015-12-28 CA CA2972265A patent/CA2972265A1/en not_active Abandoned
- 2015-12-28 US US14/979,574 patent/US10047111B2/en not_active Ceased
-
2017
- 2017-04-17 US US15/489,650 patent/US20170218365A1/en not_active Abandoned
- 2017-06-27 US US15/634,771 patent/US10023597B2/en active Active
-
2019
- 2019-09-19 US US16/576,102 patent/USRE48887E1/en active Active
-
2020
- 2020-02-28 US US16/804,696 patent/USRE49229E1/en active Active
- 2020-08-11 US US16/990,860 patent/USRE49431E1/en active Active
-
2021
- 2021-11-11 JP JP2021183788A patent/JP7307137B2/ja active Active
- 2021-11-12 US US17/454,757 patent/US20220087531A1/en not_active Abandoned
-
2023
- 2023-06-29 JP JP2023106970A patent/JP7655971B2/ja active Active
-
2025
- 2025-03-21 JP JP2025046972A patent/JP2025102833A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513104A5 (cg-RX-API-DMAC7.html) | ||
| Ashrafizadeh et al. | Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer | |
| Li et al. | Targeting long non-coding RNAs in cancers: progress and prospects | |
| Gandhi et al. | Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances | |
| Sadakierska-Chudy | MicroRNAs: diverse mechanisms of action and their potential applications as cancer epi-therapeutics | |
| Hosseinahli et al. | Treating cancer with microRNA replacement therapy: A literature review | |
| Xuan et al. | MicroRNAs in colorectal cancer: small molecules with big functions | |
| Misso et al. | Mir-34: a new weapon against cancer? | |
| Swaminathan et al. | RNA interference and nanotechnology: A promising alliance for next generation cancer therapeutics | |
| Krützfeldt | Strategies to use microRNAs as therapeutic targets | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| Osaki et al. | miRNA therapy targeting cancer stem cells: a new paradigm for cancer treatment and prevention of tumor recurrence | |
| Biersack | Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention | |
| Fahmy et al. | Molecular engines, therapeutic targets, and challenges in pediatric brain tumors: a special emphasis on hydrogen sulfide and RNA-based nano-delivery | |
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| MX2020011796A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX2020011780A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| BR112013019105A2 (pt) | nanopartículas carregadas com medicamento antitumoral quimioterapêutico | |
| Yang et al. | Potential of miRNA-based nanotherapeutics for uveal melanoma | |
| Mollah et al. | Overcoming therapy resistance and relapse in TNBC: Emerging technologies to target breast cancer-associated fibroblasts | |
| Ballarín-González et al. | Polycation-based nanoparticles for RNAi-mediated cancer treatment | |
| Yang et al. | Recent advances in extracellular vesicles enriched with non-coding RNAs related to cancers | |
| Teo et al. | Tiny miRNAs play a big role in the treatment of breast cancer metastasis | |
| JP2016526021A5 (cg-RX-API-DMAC7.html) | ||
| Mirzaei et al. | MicroRNAs in cancer |